NEWS: JULY 2004

-7/30/2004-

SCOLR Inc. changes its name to SCOLR Pharma Inc. To read article click here.

European Union committee in favor of Amgen Inc.'s drug Mimpara for kidney disease or parathyroid carcinoma treatment. To read article click here.

-7/29/2004-

FDA approves Campral® (Acamprosate Calcium) for the treatment of alcoholism. To read article click here.

Curis Inc. receives U.S. patent 6,767,888, entitled "Neuroprotective methods and reagents." To read article click here.

Anadys Pharmaceuticals Inc. and Roche form drug discovery collaboration. To read article click here.

MDS Proteomics changes its name to Protana Inc. To read article click here.

-7/28/2004-

Takeda Pharmaceuticals Co. Ltd. and Lexicon Genetics Inc. form hypertension research collaboration. To read article click here.

Organon signs agreement to use Gene Logic's toxicogenomic platform. To read article click here.

Targeted Genetics Corp. sales subsidiary CellExSys Inc. to Chromos Molecular Systems Inc. To read article click here.

-7/27/2004-

Affymetrix Inc. sues Illumina Inc. To read article click here.

Merck KGaA to file Erbitux for head and neck cancer in 2005. To read article click here.

Sunesis Pharmaceuticals Inc. and Merck & Co. Inc. form antiviral research collaboration. To read article click here.

ViroPharma Inc. to initiate Phase II clinical trials of Maribavir for the inhibition of cytomegalovirus in bone marrow transplant patients. To read article click here.

Chemaxon provides free software for academics via the Jchem and Marvin Academic Package. To read article click here.

-7/26/2004-

Mylan Laboratories Inc. to acquire King Pharmaceuticals Inc for about $3.37 billion in stock. To read article click here.

Codexis Inc. and Pfizer Inc. sing multi-year process development collaboration. To read article click here.

Boston Life Sciences Inc. files Investigational New Drug (IND) application with the FDA to use of Axosine™ in stroke recovery. To read article click here.

Amylin Pharmaceuticals Inc. receives $5 million milestone payment from Eli Lilly and Co. To read article click here.

Arena Pharmaceuticals Inc. initiates Phase 1b clinical trials of APD356 for obesity. To read article click here.

Kosan Biosciences Inc. initiates Phase Ib clinical trial of KOS-862 in a combination chemotherapy study with Paraplatin® for solid tumors. To read article click here.

-7/16/2004-

Press Release: Available from Genetix the Protein Portfolio Platform is a powerful combination of proven automation, on-board intelligent imaging and information tracking tools that delivers unprecedented performance and confidence in data fidelity helping accelerate workflows and make cost savings in drug discovery and basic protein research. To read press release click here.

King Pharmaceuticals Inc. appoints Brian A. Markison president and CEO. To read article click here.

GlaxoSmithKline and Vertex Pharmaceuticals Inc.'s anti-HIV drug Telzir® receives European approval. To read article click here.

-7/15/2004-

Press Release: A new range of affordably priced 96-well plates for use with Polymerase Chain Reaction (PCR) assays has been announced by Porvair Sciences, the leading European supplier of specialist microplates and microplate accessories. To read press release click here.

FDA approves American Pharmaceutical Partners Inc.'s Tobramycin for infection treatment. To read article click here.

FDA grants Transkaryotic Therapies Inc.'s experimental drug duronate-2-sulfatase for Hunter syndrome "fast track" review status. To read article click here.

Cell Genesys Inc. initiates Phase III clinical trials of GVAX® prostate cancer vaccine. To read article click here.

Avigen Inc. to cut 39 percent of its work force. To read article click here.

Avant Immunotherapeutics Inc.'s Rotarix vaccine is approved in Mexico. To read article click here.

BioGentech Corp. changes its name to Cobalis Corp. To read article click here.

CancerVax Corporation licenses drug dandidate that targets the EGFR signaling pathway. To read article click here.

Neurobiological Technologies Inc. acquires Empire Pharmaceuticals Inc. To read article click here.

Myogen Inc. to begin Phase II clinical trials of Darusentan for resistant systolic hypertension. To read article click here.

-7/14/2004-

Press Release: The EZ-2 Inert Purge unit from Genevac Ltd. offers a convenient and cost-effective way to meet the requirements for solvent removal in a Safe Zone as set out by the ATEX directives. To read press release click here.

Press Release: ChromSolutions (Hemel Hempstead UK) has introduced specialised training courses and consultancy specifically in sample preparation and handling procedures for the chromatographer. To read press release click here.

Press Release: Strategic Analysis of the Breast Cancer Therapeutics Pipeline: Pharmaceutical- Biotech Partnerships Generate Wave of Novel Breast Cancer Therapeutics. To read press release click here.

Applera Corp. to cut 145 jobs. To read article click here.

Celera Genomics Group and Syrrx Inc. publish in the journal Structure the x-ray structure of human histone deacetylase 8 (HDAC8) complexed with inhibitor. To read article click here.

SciClone Pharmaceuticals Inc.'s president & CEO resigns. To read article click here.

Integrated BioPharma Inc. to acquire Hauser Contract Research Organization. To read article click here.

Panacos Pharmaceuticals discloses new anti-AIDS drug candidate PA-457. To read article click here.

-7/13/2004-

Press Release: Tecan Systems Inc. announces the launch of its newest and most versatile high performance syringe pump: the Cavro® XLP 6000. To read press release click here.

Press Release: A new technical paper from ESA describes how the company has developed a unique electrochemistry based approach to answer many questions about a compound's metabolic behaviour. To read press release click here.

Progen Industries Limited initiates Phase II clinical trials of PI-88 for liver cancer treatment. To read article click here.

Seattle Genetics Inc. signs agreement with Albany Molecular Research Inc. for the manufacturing of antibody-drug conjugate. To read article click here.

Vertex Pharmaceuticals Inc. and GlaxoSmithKline's HIV protease inhibitor Lexiva provides positive results when taken in combination with with abacavir and lamivudine in 2-year study. To read article click here.

Invitrogen Corp. creates the Biological Defense Systems™ Inc. To read article click here.

Metabasis Therapeutics Inc. publishes in the Journal of the American Chemical Society new molecular modeling technology in article entitled "Development of a Quantum Mechanics-Based Free-Energy Perturbation Method: Use in the Calculation of Relative Solvation Free Energies". To read article click here.

-7/12/2004-

Press Release: Results from a multi-site study evaluating two new assays from Guava Technologies Inc. that dramatically lower the cost and difficulty of AIDS diagnosis and treatment monitoring were presented at the 15th International AIDS Conference, held July 11 - 17 in Bangkok, Thailand. To read press release click here.

Press Release: Morphochem appoints Sijmen de Vries as CEO. To read press release click here.

FDA grants fast-track status to Cell Therapeutics' pixantrone for aggressive non-Hodgkin's lymphoma treatment. To read article click here.

FDA rejects Allergan's drug candidate Tazoral for psoriasis treatment. To read article click here.

Biomira Inc. and Phenomenome Discoveries Inc. form drug discovery collaboration for cancer markers. To read article click here.

-7/02/2004-

Novartis files for to the European Union for approval of its asthma drug Xolair. To read article click here.

Mylan Laboratories Inc. to pay $9 million to Mayne Pharma and Tapestry Pharmaceuticals Inc. to settle litigation over anti-cancer drug paclitaxel. To read article click here.

DuPont Co. completes the acquisition of MaxyGen Inc.'s Verdia plant sciences unit for $64 million in cash. To read article click here.

-7/01/2004-

Ilex Oncology Inc. shareholders approve acquisition Genzyme Corp. To read article click here.

Advancis Pharmaceutical Corp. acquires U.S. rights to Eli Lilly and Co.'s Keflex® brand. To read article click here.

Geron Corporation publishes in the July 2004 issue of the journal Neuro-Oncology preclinical data of its first-generation telomerase inhibitor drug GRN163 in models of human glioblastoma. To read article click here.

Compugen Ltd. launches new subsidiary focused on small molecule drug discovery: Keddem Bioscience Ltd. To read article click here.

The National Institute of Allergy and Infectious Diseases (NIAID) cancels 5-year HIV contract with Novavax Inc. To read article click here.